Testing effectiveness (Phase 2)Ended earlyNCT02587650
What this trial is testing
Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
Who this might be right for
ALK Fusion Protein ExpressionBRAF wt AlleleInvasive Skin Melanoma+12 more
University of California, San Francisco 1